(FRLN) – Globe Newswire
-
Acquisition of Freeline by Syncona Becomes Effective
-
Freeline Shareholders Approve Acquisition by Syncona
-
Syncona to Acquire Freeline Therapeutics
-
Freeline Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease at ESGCT 30th Annual Congress
-
Freeline to Present New Clinical Data for FLT201 in Gaucher Disease in Oral Presentation at Upcoming ESGCT 30th Annual Congress
-
Freeline Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease
-
Freeline Reports Second Quarter 2023 Financial Results and Business Highlights
-
Freeline Therapeutics to Host Second Quarter 2023 Financial Results Call
-
Freeline to Participate in Upcoming Investor Conferences
-
Freeline to Host Virtual KOL Event on its Gene Therapy Candidate, FLT201, in Gaucher Disease
-
Freeline Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-linked Parkinson’s Disease
-
Freeline to Present at 2023 Jefferies Healthcare Conference
-
Freeline Reports First Quarter 2023 Financial Results and Business Highlights
-
Freeline Granted ILAP Designation in United Kingdom by MHRA for FLT201, an Investigational Gene Therapy for the Treatment of Gaucher Disease
-
Freeline Completes ADS Ratio Change
-
Freeline Announces Proposed ADS Ratio Change
-
ProQR Announces Annual Meeting of Shareholders to be Held May 17, 2023
-
Freeline to Present at 22nd Annual Needham Virtual Healthcare Conference
-
Forcefield Therapeutics signs exclusive patent and know-how license agreement with Freeline Therapeutics
-
Freeline Reports Full Year 2022 Financial Results and Provides Corporate Update
-
Freeline Therapeutics to Host Full Year 2022 Financial Results Call
-
Freeline Announces Closing of Sale of Its CMC-Focused German Subsidiary
-
Freeline Reports January 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Freeline Publishes Preclinical Proof-of-Concept Data for FLT190, its AAV Gene Therapy Candidate for Fabry Disease, in the Nature Journal Gene Therapy
-
Freeline Reports December 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Freeline Receives Approval to Transfer to Nasdaq Capital Market
-
Freeline Reports Third Quarter 2022 Financial Results and Corporate Update
-
ProQR Announces Third Quarter 2022 Operating and Financial Results
-
Freeline to Present at the Stifel Healthcare Conference
-
Freeline Reports October 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
X4 Pharmaceuticals Announces Appointment of Industry Veteran Mark Baldry as Chief Commercial Officer
-
Freeline Announces September 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Freeline Initiates Dosing of Second Cohort in MARVEL-1 Trial of FLT190 Gene Therapy Candidate for People with Fabry Disease
-
Freeline Announces August 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Freeline Reports Second Quarter 2022 Financial Results and Business Highlights
-
Freeline Announces July 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
New England Journal of Medicine Publishes Positive Long-Term Data on Freeline’s Gene Therapy Candidate FLT180a for People with Hemophilia B
-
New England Journal of Medicine Publishes Positive Long-Term Data on Freeline’s Gene Therapy Candidate FLT180a for People with Hemophilia B
-
Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress
-
Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress
-
Genespire appoints Dr. Sabah Sallah as Chief Medical Officer
-
Freeline Announces June 2022 Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Freeline Announces June 2022 Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemostasis Congress
-
Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemostasis Congress
-
Freeline Initiates Dosing of Second Cohort in B-LIEVE Dose Confirmation Trial of FLT180a in Hemophilia B
-
Freeline Initiates Dosing of Second Cohort in B-LIEVE Dose Confirmation Trial of FLT180a in Hemophilia B
-
Freeline Announces May 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Freeline Announces May 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Freeline Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
Back to FRLN Stock Lookup
